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Abstract
Heparanase is a b-D-endoglucuronidase that cleaves heparan sulfate (HS), facilitating degradation of the extracellular matrix
(ECM) and the release of HS-bound biomolecules including cytokines. The remodeling of the ECM by heparanase is
important for various physiological and pathological processes, including inflammation, wound healing, tumour
angiogenesis and metastasis. Although heparanase has been proposed to facilitate leukocyte migration through
degradation of the ECM, its role in inflammation by regulating the expression and release of cytokines has not been fully
defined. In this study, the role of heparanase in regulating the expression and release of cytokines from human and murine
immune cells was examined. Human peripheral blood mononuclear cells treated ex vivo with heparanase resulted in the
release of a range of pro-inflammatory cytokines including IL-1b, IL-6, IL-8, IL-10 and TNF. In addition, mouse splenocytes
treated ex vivo with heparanase resulted in the release of IL-6, MCP-1 and TNF. A similar pattern of cytokine release was also
observed when cells were treated with soluble HS. Furthermore, heparanase-induced cytokine release was abolished by
enzymatic-inhibitors of heparanase, suggesting this process is mediated via the enzymatic release of cell surface HS
fragments. As soluble HS can signal through the Toll-like receptor (TLR) pathway, heparanase may promote the
upregulation of cytokines through the generation of heparanase-cleaved fragments of HS. In support of this hypothesis,
mouse spleen cells lacking the key TLR adaptor molecule MyD88 demonstrated an abolition of cytokine release after
heparanase stimulation. Furthermore, TLR4-deficient spleen cells showed reduced cytokine release in response to
heparanase treatment, suggesting that TLR4 is involved in this response. Consistent with these observations, the pathway
involved in cytokine upregulation was identified as being NF-kB-dependent. These data identify a new mechanism for
heparanase in promoting the release of pro-inflammatory cytokines that is likely to be important in regulating cell migration
and inflammation.
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Introduction
Inflammation is an important innate immune response to
remove injurious stimuli and is mediated by a complex array of
soluble molecules and leukocytes that are resident and/or
attracted to the site of inflammation. It is well described that
inflammation also contributes to many diseases including arthritis,
atherosclerosis, diabetic nephropathy and cancer [1–6]. The
migration and activation of leukocytes in inflammation are
regulated by the action of chemokines and cytokines. Leukocytes
also express enzymes that degrade the extracellular matrix (ECM)
to aid their migration to sites of inflammation [7,8]. Heparan
sulfate (HS) is a key structural component of the ECM and
basement membrane (BM) which binds an array of growth factors,
chemokines and cytokines [9,10]. The only known mammalian
endoglycosidase to cleave HS is the b-D-endoglucuronidase
heparanase (HPSE) [11,12].
HPSE has been implicated in the regulation of various
physiological and pathological processes. The cleavage of HS by
HPSE expressed in cells such as activated leukocytes, metastatic
tumour cells and proliferating endothelial cells has been proposed
to facilitate degradation of the ECM/BM to promote cell
migration as well as the liberation of bioactive HS-bound
molecules associated with inflammation, tumour metastasis and
angiogenesis [13–16]. HPSE also has non-enzymatic functions
including cell adhesion, cellular differentiation and the activation
of intracellular signaling pathways [17–20].
HPSE has been implicated in inflammation by regulating
cellular migration via direct cleavage of the ECM and by
promoting the cellular adhesion properties of migrating cells
[21,22]. When heparanase is overexpressed in transgenic mice, an
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enhanced response to delayed type hypersensitivity (DTH) and
wound healing is observed [23,24]. Mouse models have also
highlighted the role of HPSE in type 1 diabetes (T1D) by showing
that when HPSE cleaves the HS barrier around pancreatic islet
BMs, induction of T1D can occur [25]. When treated with the
HPSE inhibitor PI88, diabetes-prone NOD mice display preserved
islet beta cell HS and reduced incidence of islet inflammation and
T1D [25,26]. Furthermore, when HPSE activity is blocked with
competitive inhibitors, sepsis-induced glomerular dysfunction and
inflammation are attenuated in a polymicrobial sepsis mouse
model [27]. HPSE has also been implicated in the severity of
atherosclerosis, as expression is increased in coronary vulnerable
plaques as opposed to stable plaques and controls [28]. HPSE
expression is also observed in the colon of patients suffering from
Crohn’s disease and ulcerative colitis [29,30], and similarly in the
synovial fluid and tissue of patients suffering from rheumatoid
arthritis, but not in unaffected individuals [31]. In addition, HPSE
has been implicated in central nervous system inflammatory
disorders such as multiple sclerosis. Initial reports suggested that
HPSE may promote experimental autoimmune encephalomyelitis
(EAE), a murine model of MS, as (i) HPSE was shown to be highly
expressed in infiltrating cells during EAE [32], and (ii) that the
inhibition of HPSE reduced symptoms of EAE correlating with
reduced lesions in the spinal cord [33,34]. In contrast, a recent
study has suggested an inhibitory role for HPSE in EAE, as
administration of exogenous HPSE prior to the initiation of
disease, actually resulted in ablation of symptoms [35].
Despite the proposed importance of HPSE in inflammation, its
role in cytokine regulation has only recently been examined,
whereby Blich and colleagues proposed that HPSE plays a direct
role as a signaling molecule to stimulate the release of cytokines
from primary mouse peritoneal macrophages or the mouse
macrophage cell line J774 [28]. In this study, to further define
the mechanism of action for heparanase in cytokine release,
immune cells were treated with exogenous endotrap-purified
heparanase, and cytokine release examined. HPSE was shown to
stimulate the release of pro-inflammatory cytokines from human
peripheral blood mononuclear cells (PBMCs) and mouse spleno-
cytes. Interestingly, a similar trend was observed after stimulation
of human PBMCs with soluble HS fragments, indicating that
HPSE may be triggering the release of cytokines indirectly via the
liberation of HS fragments from the cell surface and possible
signaling through toll like receptors (TLRs) [36]. Indeed, this
mechanism was supported by the significant reduction of cytokine
release when HPSE was treated with enzymatic inhibitors and that
HPSE-induced cytokine release was shown to be dependent on
MyD88 and in part through TLR-4 via the NF-kB pathway.
Thus, this study demonstrates that HPSE can initiate cytokine
release from immune cells by generating soluble HS fragments
that activate TLR-dependent pathway(s).
Results
HPSE promotes the release of pro-inflammatory
cytokines from human PBMCs
Native HPSE was purified from human platelets [37] and
passed through an endotoxin-removal column [38]. Mass spec-
trometry and SDS-PAGE analysis confirmed the identity of HPSE
(Fig. S1A-B) and HS-cleaving enzyme activity was confirmed by a
TR-FRET activity assay (Fig. S1C) [39].
To investigate the ability of HPSE to modulate the release of
pro-inflammatory cytokines, human PBMCs were isolated from
whole blood and treated with exogenous endotrap-purified HPSE,
upon which the levels of a panel of pro-inflammatory secreted
cytokines (IL-8, IL-6, IL-1b, TNF, IL-10 and IL-12p70) were
determined using a cytometric bead array (CBA) assay. When
treated with 10 mg/ml HPSE, a 10- to 50-fold increase in the level
of cytokines in the sample supernatants at 12 h post-incubation for
each of IL-8, IL-6, IL-1b, TNF and IL-10 (Fig. 1). In contrast,
there was no change in levels of IL-12p70. Furthermore, the ability
of HPSE to stimulate cytokine release was concentration
dependent (data not shown).
HPSE induces gene expression of pro-inflammatory
cytokines from human PBMCs
To determine whether increased cytokine release was associated
with an upregulation of cytokine gene expression, mRNA levels of
a panel of cytokines following HPSE treatment were determined
by qPCR. All of the pro-inflammatory cytokines tested, with the
exception of IL-12p35, showed a significant increase in mRNA
levels after 4 or 16 h of HPSE treatment but this had reduced by
24 h (Fig. 2). Interestingly, the kinetics of cytokine gene expression
could be divided into three groups; genes that showed (i) rapid
upregulation, (ii) slow upregulation and (iii) no change. IL-6, IL-8
and IL-10 showed low expression at 4 h with peak expression at
16 h, whereas TNF and IL-1b showed high expression at 4 h that
increased slightly by 16 h. IL-12p35 mRNA levels showed no
significant change following HPSE treatment of cells compared
with the untreated control, consistent with that observed for IL-
12p70 protein levels.
Cytokine response to HPSE is not due to endotoxin
contamination
It has been well documented that LPS contamination of purified
proteins can induce cytokine upregulation via signalling through
TLRs [40]. Indeed, there have been many cases in which proteins
were proposed to upregulate cytokine regulation, which was later
found to be not reproducible due to endotoxin contamination
[41–43].
Although HPSE was purified from human platelets and not a
bacterial source in this study, to confirm that cytokine upregula-
tion was not due to any potential endotoxin contamination,
endotrap-purified HPSE, or a control of endotrap-purified DMG
buffer alone, was treated with proteinase-K conjugated to agarose
beads to degrade HPSE, therefore essentially removing the active
protein from the sample. After treatment, proteinase-K was
removed from the sample via the removal of the agarose beads.
The degradation of HPSE in proteinase-K-treated samples was
confirmed by Western blot analysis, as well as by a TR-FRET
activity assay (Fig. 3A and B). The Western blot indicated an
almost complete loss of HPSE following treatment with proteinase-
K, with only minor amounts remaining (Fig. 3A). The activity
assay essentially showed a complete reduction of HPSE enzymatic
activity in the treated sample, with levels comparable to the
background level of HPSE-free proteinase-K treated media
(Fig. 3B). PBMCs were then treated with media alone, protein-
ase-K treated buffer, HPSE, or proteinase-K treated HPSE. For
each of the cytokines examined, levels were significantly reduced
when cells were stimulated with proteinase-K treated HPSE, as
compared to cells treated with active, intact HPSE (Fig. 3C).
However, it should be noted that proteinase-K-treated HPSE was
still able to induce the release of pro-inflammatory cytokines from
PBMCs compared to the control media alone (Fig. 3C), possibly
due to the residual levels of intact HSPE in proteinase-K treated
samples (Fig. 3A). Furthermore, proteinase-K treatment did not
significantly reduce LPS-induced cytokine release (Fig. S2), ruling
out any direct effect of proteinase-K on LPS. Therefore, the ability
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of platelet-purified HPSE to stimulate the release of pro-
inflammatory cytokines is unlikely to be due to contaminating
endotoxins.
Soluble HS mediates cytokine release
A potential mechanism of action for HPSE in mediating
cytokine release is via the libration of HS fragments from the cell
surface that may trigger downstream signaling events. HPSE
cleaves HS at regions of high sulfation, resulting in the release of
5–7 kDa soluble HS fragments [44]. Soluble HS fragments have
also been shown to signal through a range of receptors on the cell
surface, including Eph receptors [45] and TLRs [46]. Initially, to
determine whether HPSE can cleave cell surface HS under
conditions used to stimulate the release of cytokines, cells were
treated with HPSE or the positive control of proteinase-K, and the
level of cell surface HS was determined by flow cytometry. After
1 h HPSE treatment, the level of cell surface HS (as indicated by
fluorescent intensity of HS staining) was greatly reduced,
indicating that HPSE is cleaving HS (Fig. 4A). Proteinase-K
treated cells also showed a significant loss of fluorescence as
proteinase-K removes cell surface HS-proteoglycans. To address
whether HS fragments can stimulate cytokine release, the effect of
fragmented HS on human PBMCs was initially investigated. Prior
to these experiments, short chain porcine HS was passed through
endotoxin-removal columns (as described for HPSE). Soluble
endotrap-purified HS fragments induced the release of a similar
pattern of cytokines (IL-1b, IL-6, IL-8, IL-10 and TNF) from
PBMCs as described for HPSE (Fig. 4B), suggesting that HPSE
may be mediating the release of cytokines indirectly by cleaving
HS from the cell surface, which triggers cytokine release.
HPSE-induced cytokine release is dependent on the
enzymatic activity of heparanase
To determine whether HPSE is acting in an enzymatic or a
signalling manner to induce cytokine release, the HPSE inhibitors
OGT 2115 [44,47] or heparin [48,49] were used to block the
enzymatic function of HPSE. The enzymatic activity of HPSE was
significantly reduced in the presence of OGT 2115 or heparin, as
determined by a HPSE activity assay (Fig 5A). When treated with
HPSE in the presence of OGT 2115 or heparin, human PBMCs
showed significantly reduced levels of cytokine release (IL-8, IL-6,
IL-1b, IL-10 and TNF) in comparison to cells treated with
enzymatically active HPSE or inhibitors alone (Fig. 5B).
Figure 1. HPSE mediates release of pro-inflammatory cytokines from human peripheral blood mononuclear cells. Quantitation of IL-8,
IL-6, IL-1b, TNF, IL-10 and IL-12p70 released by human PBMCs after treatment with 10 mg/mL exogenous endotrap-purified HPSE for 16 h, using a
human pro-inflammatory CBA assay. Data represent the mean 6SEM of triplicate samples, representative of three independent experiments. *p =
,0.05, **p =,0.001 unpaired, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0109596.g001
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HPSE-induced cytokine release is through a
MyD88-dependent pathway
The TLR family plays a key role in the innate immune system
and some members are known to be receptors for soluble HS [36].
Therefore, TLRs represent attractive candidates for the signalling
of HPSE generated HS fragments. As MyD88 is an adaptor
protein essential for signal transduction of cell-surface TLRs [50],
splenocytes from MyD882/2 or WT mice were isolated and
treated with HPSE. Consistent with human PBMCs, in response
to HPSE stimulation, WT mouse splenocytes were able to release
cytokines, including MCP-1, IL-6 and TNF (Fig. 6). However,
when MyD882/2 splenocytes were stimulated with HPSE, the
levels of these cytokines released were significantly reduced in
comparison to WT (Fig. 6). To confirm in this model system that
deletion of MyD88 resulted in the loss of signalling through TLRs,
LPS was used as a positive control, as it evokes a strong response in
cytokine release through TLR4 [51]. In contrast to WT
splenocytes, MyD882/2 splenocytes showed a complete lack of
cytokine release when stimulated with LPS (Fig. 6).
HPSE-induced cytokine release is partially dependent
upon the TLR4 receptor
As soluble HS has been proposed to activate TLR4 [52], to
identify the MyD88-dependent receptor involved in HPSE-
mediated cytokine release, splenocytes from TLR42/2 or WT
mice were isolated and treated with either HPSE or the TLR4-
specific agonist LPS. Interestingly, while LPS-mediated release of
MCP-1, IL-6 and TNF was completely abolished in TLR42/2
cells, HPSE-mediated cytokine release was significantly but not
completely reduced (Fig. 7). Therefore, these data suggest that
TLR4 plays an important role in HPSE-induced cytokine release,
but may not be the only receptor upstream of MyD88 involved in
this process.
Extracellular HPSE stimulates the NF-kB pathway
TLR signaling pathways classically culminate in the activation
of the transcription factor nuclear factor kappa B (NF-kB) [53].
Based on the involvement of TLRs in HPSE-mediated cytokine
release, SV40T immortalised mouse embryonic fibroblasts (MEFs)
transfected with pTRH1-NF-kB-GFP, which exhibit GFP fluo-
rescence if the NF-kB reporter is cleaved in either a canonical or
non-canonical pathway [54] were examined. When treated with
HPSE, reporter cells showed a significant increase in GFP mean
fluorescent intensity (MFI), with an approximate 10-fold increase
of fluorescence after 3 h incubation (Fig. 8). The kinetics of NF-kB
cleavage was investigated, with a three-fold increase in GFP MFI
after 1 h, which increases to a ten-fold in GFP MFI by 3 h. As a
control, LPS showed maximal fluorescence at 3 h stimulation
(Fig. 8). These results suggest that HPSE is acting through NF-kB
to upregulate the transcription and translation of pro-inflamma-
tory cytokines.
Figure 2. HPSE induces gene expression of pro-inflammatory cytokines from human peripheral blood mononuclear cells. Expression
of IL-8, TNF, IL-1b, IL-6, IL-10 and IL-12p35 mRNA by RT-PCR in PBMCs incubated in the presence or absence of 10 mg/ml HPSE for 4, 12 or 24 h. Data
are expressed as the mean level of expression normalised to ubc e2d2, data represent the mean6SEM of triplicate samples, results are representative
of three independent experiments. *p =,0.05, **p =,0.001 unpaired, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0109596.g002
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Discussion
HPSE is the only known mammalian endoglycosidase with the
ability to directly cleave HS, and plays an important role in ECM
remodeling in a number of physiological and pathological settings.
HPSE has been implicated in inflammatory disorders including
arthritis, multiple sclerosis, inflammatory bowel disease and
atherosclerosis [29,31,32,55]. Pro-inflammatory cytokines make
Figure 3. Proteinase-K treated HPSE results in a reduced cytokine response in PBMCs. HPSE (1 mg) was treated with proteinase-K agarose
beads (80 mg/ml) for 30 min at 37uC before removal of proteinase-K agarose beads and SDS-PAGE analysis. (A) Western blot analysis for HPSE confirms
that proteinase-K treatment dramatically reduced intact HPSE levels in the sample. (B) HPSE activity assay on identically treated samples of either HPSE
alone, proteinase K alone, or HPSE treated with proteinase K. Data represent the mean 6SEM (n= 3). (C) Expression of cytokines after stimulation with
proteinase-K treated HPSE in IL-1b, IL-6, IL-10, IL-8 and TNF in PBMCs isolated from human whole blood. Data represent the mean 6SEM of triplicate
samples, results are representative of three independent experiments. *p=,0.05, **p=,0.001; unpaired, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0109596.g003
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important contribution to all of these inflammatory diseases. This
study shows that HPSE promotes the release of pro-inflammatory
cytokines from both human and murine immune cells, possibly via
a novel mechanism involving the generation soluble HS fragments,
leading to the activation of TLR signaling.
A number of studies have implicated HPSE in the regulation of
cytokine expression. The down-regulation of HPSE expression
using RNA interference resulted in decreased levels of mRNA and
protein of IL-8 and chemokine (C-X-C motif) ligand 1 (CXCL1) in
the human malignant melanoma cell line A375 [56]. In vivo
studies by Bitan and colleagues have shown that splenocytes
isolated from mice injected with active recombinant HPSE over a
period of eight days express increased levels of Th2 cytokines IL-4,
IL-6 and IL-10, but decreased levels of Th1 cytokines IL-12 and
TNF-a [35]. However, it should be noted that potential endotoxin
contamination of recombinant HPSE would mediate a similar
effect, a possibility that was not excluded in the latter study [35].
Herein, we describe that purified native human HPSE when
added to in vitro cell cultures, induced the release of pro-
inflammatory cytokines IL-1b, IL-6, IL-8, IL-10 and TNF from
human PBMCs, and MCP-1, IL-6 and TNF from mouse
splenocytes. It should be noted that although IL-10 is pro-
Figure 4. HPSE cleaves HS from the cell surface, and soluble HS leads to cytokine release. (A) The ability of HPSE to cleave HS in in vitro
conditions was examined by treating cells with either the positive control of PK (100 mg/mL) or HPSE (10 mg/mL) for 1 h before staining for the
presence of cell-surface HS, and analysing by flow cytometry. MFI of representative overlaid histograms of untreated (grey-filled curve), HPSE treated
(empty black line), or PK treated cells (dotted line). (B) Endotrap-purified HS fragments (50 mg/mL) were added to PBMCs for the indicated time,
before the supernatant was used in a human CBA pro-inflammatory assay to quantify cytokine release. Data represent the mean 6SEM of triplicate
samples, results are representative of three independent experiments. *p =,0.05, **p =,0.001; unpaired, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0109596.g004
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Figure 5. HPSE-induced cytokine release is dependent on the enzymatic activity of heparanase. (A) HPSE (1 ng) was treated with the
enzymatic inhibitors heparin (10 ng) or OGT 2115 (20 ng) for 10 min at 37uC. HPSE activity assays were performed on treated samples of either HPSE
alone, buffer or inhibitors alone, or HPSE treated with inhibitors. Data represent the mean 6SEM (n= 3). (B) Expression of cytokines (IL-8, IL-6, IL-1b,
TNF and IL-10) by human PBMCs isolated from whole blood after stimulation with heparanase (10 mg/ml) treated with enzymatic inhibitors heparin
(100 mg/ml) or OGT 2115 (200 mg/ml) for 24 h. Data represent the mean 6SEM of triplicate samples, results are representative of three independent
experiments. *p =,0.05, **p =,0.001; unpaired, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0109596.g005
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inflammatory in certain settings, it also has anti-inflammatory
functions [57,58]. All experiments used enzymatically active
HPSE isolated from human platelets that was endotrap-purified
to remove potential endotoxin contamination. Furthermore,
HPSE preparations treated with proteinase-K to remove the
enzyme led to significantly reduced cytokine upregulation,
indicating that HPSE and not endotoxin was responsible for the
effect.
A recent study has suggested that HPSE acts independently of
its enzymatic activity to release pro-inflammatory cytokines.
Murine splenocytes treated with IL-2 and the 65 kDa latent pro-
form of human HPSE were shown to release cytokines [35].
However, it is important to note that this effect could be also
explained by the HPSE precursor being processed in the cell
system to produce an active enzyme. Herein we suggest that HPSE
enzymatically cleaves HS on cell surfaces and the resultant soluble
HS can in turn stimulate the release of pro-inflammatory cytokines
from human and mouse primary immune cells (Fig. 9). HPSE
when treated with the enzymatic inhibitors heparin and OGT
2115 resulted in the abolition of cytokine release from human
PBMC. Therefore, in contrast to previous studies, these data
suggest that HPSE-mediated cytokine upregulation is likely to be
dependent on the HS-degrading activity of the enzyme via the
generation of HS fragments, at least in part.
The ability of HS to modulate the function of cytokines has
been proposed for many years, with several studies indicating that
HS inhibits proteolysis of cytokines and increases the activity of
cytokines by assisting their multimerisation [59,60]. Furthermore,
Figure 6. HPSE dependent cytokine release is via a MyD88-dependent pathway. Mouse splenocytes from WT and MyD882/2 mice were
isolated and treated with HPSE (10 mg/mL) or LPS (100 nM) for the indicated time, before the supernatant was analysed using the CBA assay for the
mouse pro-inflammatory cytokines MCP-1, IL-6 and TNF. Data represent the mean 6SEM of triplicate samples, results are representative of three
independent experiments. *p =,0.05, **p=,0.001; unpaired, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0109596.g006
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soluble HS has also been shown to act directly through TLRs to
promote DC maturation and function as well as T-cell
alloreactivity, which has the potential to increase the severity of
inflammatory disorders such as graft-versus-host disease (GVHD)
[61]. Blich and colleagues have recently suggested that HPSE
triggers cytokine release by acting as a signaling molecule through
a direct interaction with TLR4, and possibly TLR2, as an
enzymatically inactive mutant of HPSE leads to the same cytokine
release as WT HPSE [28]. Interestingly, in the current study, all
HPSE-mediated pro-inflammatory cytokine release was signifi-
cantly reduced in TLR42/2 splenocytes, whereas the study by
Blich and colleagues showed a reduction in TLR42/2 mouse
peritoneal macrophages for TNF-a levels whereas MCP-1 levels
increased [28]. This raises the possibility that there are both HPSE
enzymatic and non-enzymatic mechanisms involved in promoting
pro-inflammatory cytokine release.
The results described herein indicate that HPSE-mediated
cytokine release is MyD88-dependent and primarily involves
TLR4. However, as HPSE-mediated cytokine release was not
completely abolished in TLR42/2 splenocytes, other receptor(s)
upstream of MyD88 are also likely to make a contribution. Indeed,
as indicated above, TLR2 has previously been implicated in
HPSE-mediated cytokine release [28]. To precisely define the
relative contributions of the TLRs in this process, additional
studies are necessary using TLR22/2/TLR42/2 cells. We have
also shown that cytokine expression in response to HPSE is
transcriptionally regulated, and this result is consistent with HS
fragments acting through TLRs via NF-kB. Indeed, HPSE-
mediated cytokine release is reduced when cells are treated with
Figure 7. HPSE signals via TLR4 to upregulate cytokine expression. Mouse splenocytes isolated from WT and TLR42/2 mice were treated
with HPSE (10 mg/mL) or LPS (100 nM) for the indicated time, before the supernatant was analysed via a mouse CBA pro-inflammatory cytokine assay
for MCP-1, IL-6, and TNF. Statistical analysis was performed on WT and TLR42/2 HPSE treated cells, as well as TLR42/2 LPS and HPSE treated cells. Data
represent the mean 6SEM (n= 5). *p =,0.05, **p=,0.001; unpaired, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0109596.g007
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the NF-kB inhibitor BAY117082 [28]. Furthermore, it is
interesting to note that resistin has recently been identified as a
new interacting partner for HPSE. Resistin has been shown to
bind and signal through TLR4, leading to an increase in the pro-
inflammatory protein MCP-1 [62,63]. How the interaction of
HPSE and resistin regulates pro-inflammatory cytokine produc-
tion is clearly of significant interest.
In conclusion, the results presented herein suggest that HPSE
can stimulate the release of pro-inflammatory cytokines by the
enzymatic generation of HS fragments that in turn act through
TLR-4 and another MyD88 dependent receptor, via NF-kB. This
identifies a novel role for HPSE enzymatic activity in the
regulation of an inflammatory response that is distinct from that
previously described in facilitating the physical breakdown of the
ECM to promote efficient migration of leukocytes to sites of
inflammation. This study therefore broadens our understanding of
HPSE function by suggesting an important multifaceted role for
the enzyme in inflammation.
Materials and Methods
Real-time PCR (RT-PCR)
Total RNA was isolated from cells using TRI Reagent RT
(Molecular Research Centre, OH) and complementary DNA
(cDNA) synthesized from 1 mg total RNA using an iScript Select
cDNA Synthesis Kit (Bio-Rad, CA). Complementary DNA was
amplified using FastStart SYBR Green Master (Roche, Germany)
with specific primers (Table 1) using the Agilent Mx300P qPCR
Figure 8. HPSE-treated cells exhibit NF-kB pathway activation. SV40T immortalised MEFS infected with pTRH1-NF-kB-GFP were treated with
HPSE (10 mg/mL) or LPS (100 nM) for the indicated time and analysed by immunofluorescence flow cytometry. (A) Representative overlaid
histograms of HPSE treated cells for 0 h (grey-filled curve), 1 h (empty black line), 2 h (dotted line) and 3 h (dashed lines). (B) MFI calculated from the
histograms. Data represent the mean 6SEM (n= 6). * = p,0.05, ** = p,0.001; unpaired, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0109596.g008
Figure 9. Model of cytokine upregulation in response to HPSE. Schematic model of the proposed function of HPSE in releasing pro-
inflammatory cytokines. (1) HPSE cleaves and solubilises HS fragments from the cell surface of immune cells. (2) HS fragments then signal through
MyD88-dependent receptors, of which TLR4 is one, and this leads to NF-kB cleavage and activation. (3) NF-kB-dependent upregulation of cytokine
production and release, including IL-8, IL-10, IL-6, TNF and IL-1b. (4) Cytokines are involved in inflammatory events including chemoattraction and
increased antibody production. (5) These events contribute to the induction of an inflammatory response.
doi:10.1371/journal.pone.0109596.g009
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(Stratagene, CA), with annealing temperature at 58uC and
extension time of 15 seconds for all primer pairs.
Purification of native HPSE from human platelets
Purification of human HPSE from platelets was based on a
previously published method [64] with some modifications. This
study was carried out in strict accordance with La Trobe Research
Services Human Ethics Committee (permit number FHEC09R16)
in accordance with the Australian Red Cross Blood Service
agreement (number 13-05VIC-04). Expired platelets were ob-
tained from the Australian Red Cross Blood Service (West
Melbourne branch, Victoria) (http://www.donateblood.com.au/)
and pelleted via centrifugation at 1600 g for 20 min at 20uC. The
pellets were washed twice in 0.9% saline and 50–100 units of
platelets were pooled for HPSE purification. The pooled platelets
were resuspended in 4 volumes of sodium dimethyl glutarate
buffer (15 mM sodium dimethyl gluterate (Sigma Aldrich, MO),
pH 6.0, 0.5 M NaCl) and were subjected to three cycles of freeze-
thawing before centrifugation at 35,000 g for 60 min at 4uC. The
supernatant was removed and stored at 4uC before the platelets
were freeze-thawed and pelleted twice more, pooling the three
supernatants.
The supernatant, containing 0.2% Triton X-100 and 1 mM
CaCl2/MnCl2, was passed through a concanavalin A-Sepharose
(GE Healthcare, UK) column before eluting with 20% (w/v)
methyl a-D-mannopyranoside and passing through a Zn2+-
chelating sepharose column (GE Healthcare) connected in series
to a Blue A-agarose column (GE Healthcare) at 4uC and washing
with 0.5 M then 0.8 M NaCl. The Blue A-agarose column was
then connected in series to an octyl-agarose column (GE
Healthcare) and the protein was eluted from the Blue A-agarose
column with 2 M NaCl and passed through the connected
column. The eluted protein was concentrated in a YM-30
centrifugal filter (Amicon Biosciences) followed by further
concentration in a centricon YM-30 centrifugal filter (Amicon).
Endotoxin removal
Purified native HPSE and soluble HS was passed through an
endotrap red column (Hyglos GmbH, Regensburg, Germany) as
per manufacturer’s specifications, collecting 100 ml fractions. To
determine the concentration of HPSE in each sample, a BCA
assay and a quantified Western blot were performed on the
fractions. All other chemicals and samples were bought and
maintained in an endotoxin free environment.
HPSE enzymatic activity assay
HPSE activity was detected via a time-resolved fluorescence
energy transfer (TR-FRET)-based assay (Cisbio, MA) according to
manufacturer’s instructions. For inhibitor studies, 1 ng HPSE was
incubated with either OGT 2115 (20 ng) or heparin (10 ng) for
10 min at 37uC. The HPSE-treated inhibitor samples, 1 ng of
untreated HPSE or proteinase-K treated HPSE were diluted in
HPSE dilution buffer (20 mM Tris-HCl, 0.15 M NaCl, 0.1%
CHAPS, pH 5.5) before being diluted 1:1 with pure H2O and
combined with the substrate Biotin-HS-Eu(K) (0.7 mg/ml Biotin-
HS-Eu(K), 0.2 M NaCH3CO2, pH 5.5; Cisbio, MA). The
resulting reaction was incubated at 37uC for 2 h. XL665-
conjugated Streptavidin (1 mg/ml Streptavidin-XL665 (Cisbio,
MA), 0.1 M NaPO4, pH 7.5, 1.2 M KF, 0.1% BSA, 2.0 mg/ml
heparin) was then added and the reaction incubated in dark for
16 h at room temp. Excitation of 315 nm and emission of 620 nm
and 680 nm was then measured. The percentage of HS
degradation was calculated in relation to FRET positive or
negative samples (i.e. presence of absence of XL665-conjugated
Streptavidin, respectively, in the absence of HPSE). HPSE activity
was measured with a SpectroMax M5e spectrophotometer
(Molecular Devices, CA). To determine activity per protein
concentration, the final percentage of HS degradation was divided
by the absolute amount of lysates assayed.
Cytometric bead array assay
Levels of soluble cytokines were measured using a cytometric
bead array (CBA) human inflammation kit or mouse inflammation
kid (BD Biosciences) according to the manufacturer’s instructions,
using supernatant generated from stimulation of 26105 cells/well
in 96 well plates. For inhibitor studies, HPSE (10 mg/ml) was
treated with OGT 2115 (200 mg/ml) or heparin (100 mg/ml) for
10 min at 37uC before being added to cells. Samples were
analysed by flow cytometry using a FACSCalibur, and analysed
with FCAPArray Software (BD Biosciences).
Purification of PBMCs
Whole blood was diluted 1:1 with sterile pyrogen free PBS
(Gibco) and layered onto Ficoll-Paque PLUS (GE Healthcare,
Buckinghamshire, UK) before separation via centrifugation at
750 g for 30 min at room temperature, in the absence of brakes.
After separation of layers, the PBMC layer was removed from
directly above the Ficoll and washed three times in 0.1% BSA/
PBS. Cells were resuspended in 0.1% BSA/RPMI and seeded into
a microplate.
Western blotting
Western blot analysis was carried out as described previously
[39] using a rabbit anti-HPSE Ab (Hpa-1; 1:3000; InSight
Biopharmaceuticals, Israel) followed by HRP-conjugated anti-
rabbit Ig (1:10000; GE Healthcare).
Table 1. qPCR oligonucleotide sequences.
Gene Forward sequence (59 – 39) Reverse sequence (59 – 39)
UBC E2D2 GGCTCTGAAGAGAATCCACAA TTGTAGCTTGCCAATGGAAC
IL-1b GAAGCTGATGGCCCTAAACA AAGCCCTTGCTGTAGTGGTG
IL-6 AGTGAGGAACAAGCCAGAGC GTCAGGGGTGGTTATTGCAT
IL-8 CGGAAGGAACCATCTCACTG AGCACTCCTTGGCAAAACTG
IL-10 GTGGAGCAGGTGAAGAATGC GCCACCCTGATGTCTCAGTT
IL-12p35 CACTCCCAAAACCTGCTGAG GGTAAACAGGCCTCCACTGT
TNF CTGCTGCACTTTGGAGTGAT AGATGATCTGACTGCCTGGG
doi:10.1371/journal.pone.0109596.t001
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Proteinase-K treatment of HPSE
Proteinase-K-agarose beads (Sigma Aldrich) were suspended in
endotoxin free PBS (Ca2+- and Mg2+-free, Life Technologies, CA)
to a concentration of 80 mg/ml. Endotoxin-free HPSE or PBS
was treated with proteinase K-agarose beads for 1 h at 37uC. The
samples were transferred immediately to ice, before the proteinase-
K beads were removed via centrifugation at 200 g for 3 min at
4uC. Proteinase-K treated HPSE or DMG buffer control were
stored at 4uC until use in the human pro-inflammatory cytokines
assay.
Spleen cell purification and stimulation
Spleens from pathogen-free Balb/c wild-type, MyD882/2 or
TLR42/2 mice [51,65] were isolated and passed through a
100 mm cell strainer into 10 ml DMEM (Life Technologies). Cells
were washed twice with DMEM before being resuspended in
endotoxin-low 0.1% BSA/RPMI and seeded into a microplate.
This study was approved by the La Trobe University Animal
Ethics Committee (ethics approval number AEC11-34).
Heparan sulfate binding studies
Raw macrophage 264.7 (ATCC) cells were removed from the
flask with Versene (0.5 mM EDTA), washed twice with PBS and
resuspended in 0.1% BSA/PBS at 4uC. Cells were incubated with
mouse anti-HSPG Ab (Clone F58-10E4; Seikagaku, Tokyo, Japan)
for 30 min on ice before washing twice and incubating with a
secondary PE-conjugated anti-IgM Ab (eBiosciences). Cells were
washed twice before being subjected to flow cytometry on a
FACSCanto.
NF-kB-GFP stimulation assay
SV40T immortalised MEFS infected with pTRH1-NF-kB-GFP
(System Biosciences (TR503PA-1) were a kind gift from David
Vaux and James Vince (WEHI). Cells were cultured in an
endotoxin-free environment before being seeded into a 24 well
plate and treated with either 10 mg/ml HPSE or 100 nM LPS.
Cell fluorescence was measured on a FACSCanto, gating out cell
debris, and the mean fluorescent intensity (MFI) was calculated.
Supporting Information
Figure S1 HPSE purification and quality assurance. (A)
HPSE purified from human platelets was subjected to SDS-PAGE
and either stained with Coomassie or transferred to nitrocellulose
and probed with an anti-HPSE antibody. (B) Purified human
HPSE was reduced and alkylated before digestion with trypsin and
analysis by MALDI-TOF-TOF-MS. The measured masses were
assigned to HPSE sequence and coverage of 63% was achieved.
The black bars represent the identified peptides in the human
HPSE sequence. (C) HPSE activity assay of 1 ng purified HPSE,
or buffer control. Data represent the mean 6SEM (n= 3).
(TIF)
Figure S2 Proteinase-K does not significantly abolish
LPS-induced cytokine release. LPS was treated with
proteinase-K agarose beads for 30 min at 37uC before removal
of proteinase-K beads. Expression of cytokines after stimulation
with proteinase-K treated LPS in IL-8, IL-1b, IL-6, IL-10 and
TNF in human PBMCs. Data represent the mean 6SEM of
triplicate samples, results are representative of three independent
experiments). * = p,0.05, ** = p,0.001; unpaired, two-tailed
Student’s t-test.
(TIF)
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